Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Phylogenomics and population genomics of SARS-CoV-2 in Mexico reveals variants of interest (VOI) and a mutation in the Nucleocapsid protein associated with symptomatic versus asymptomatic carriers

View ORCID ProfileFrancisco Barona-Gómez, View ORCID ProfileLuis Delaye, Erik Díaz-Valenzuela, View ORCID ProfileFabien Plisson, Arely Cruz-Pérez, Mauricio Díaz-Sánchez, Christian A. García-Sepúlveda, View ORCID ProfileAlejandro Sanchez-Flores, Rafael Pérez-Abreu, Francisco J. Valencia-Valdespino, Natali Vega-Magaña, J. Francisco Muñoz-Valle, Octavio P. García-González, Sofía Bernal-Silva, View ORCID ProfileAndreu Comas-García, View ORCID ProfileAngélica Cibrián-Jaramillo
doi: https://doi.org/10.1101/2021.05.18.21256128
Francisco Barona-Gómez
1Unidad de Genómica Avanzada (Langebio), Cinvestav-IPN, Irapuato, Guanajuato, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francisco Barona-Gómez
Luis Delaye
2Departamento de Ingeniería Genética, Unidad Irapuato, Cinvestav-IPN, Irapuato, Guanajuato, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Luis Delaye
Erik Díaz-Valenzuela
1Unidad de Genómica Avanzada (Langebio), Cinvestav-IPN, Irapuato, Guanajuato, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabien Plisson
3Conacyt - Unidad de Genómica Avanzada (Langebio), Cinvestav-IPN, Irapuato, Guanajuato, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fabien Plisson
Arely Cruz-Pérez
1Unidad de Genómica Avanzada (Langebio), Cinvestav-IPN, Irapuato, Guanajuato, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauricio Díaz-Sánchez
4Molecular Biology Research & Development Department, GrupoT, Irapuato, Guanajuato, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian A. García-Sepúlveda
5Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis, San Luis Potosí, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandro Sanchez-Flores
6Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alejandro Sanchez-Flores
Rafael Pérez-Abreu
7Centro de Investigación en Matemáticas AC (Cimat), Sede Aguascalientes, Aguascalientes, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco J. Valencia-Valdespino
8Prothesia, Monterrey, Nuevo Leon, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natali Vega-Magaña
9Laboratory for the Diagnosis of Emerging and Reemerging Diseases (LaDEER), University Center for Health Sciences, University of Guadalajara, Guadalajara, Jalisco, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Francisco Muñoz-Valle
10Institute for Research in Biomedical Sciences, University Center for Health Sciences, University of Guadalajara, Guadalajara, Jalisco, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Octavio P. García-González
4Molecular Biology Research & Development Department, GrupoT, Irapuato, Guanajuato, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sofía Bernal-Silva
11Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, San Luis, San Luis Potosí, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreu Comas-García
5Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis, San Luis Potosí, Mexico
11Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, San Luis, San Luis Potosí, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andreu Comas-García
Angélica Cibrián-Jaramillo
1Unidad de Genómica Avanzada (Langebio), Cinvestav-IPN, Irapuato, Guanajuato, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angélica Cibrián-Jaramillo
  • For correspondence: angelica.cibrian@cinvestav.mx
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Understanding the evolution of SARS-CoV-2 virus in various regions of the world during the Covid19 pandemic is of the utmost importance to help mitigate the effects of this devastating disease. We describe the phylogenomic and population genetic patterns of the virus in Mexico during the pre-vaccination stage, including asymptomatic carriers. A RT-qPCR screening and phylogenomics reconstructions directed a sequence/structure analysis of the Spike glycoprotein, revealing mutation of concern E484K in genomes from central Mexico, in addition to the nationwide prevalence of the imported variant 20C/S:452R (B.1.427/9). Overall, the detected variants in Mexico show mutations in the N-terminal domain (i.e., R190M), in the receptor-binding motif (i.e., T478K, E484K), within the S1-S2 subdomains (i.e., P681R/H, T732A), and at the basis of the protein, V1176F, raising concerns about the lack of phenotypic and clinical data available for the postulated variants of interest (VOIs) 20B/478K.V1 and P.3. Moreover, the population patterns of Single Nucleotide Variants (SNVs) from symptomatic and asymptomatic carriers sampled with a self-sampling scheme, revealed a bimodal distribution of polymorphisms in all three sampled localities from central Mexico, and confirmed the presence of several fixed variants, mostly from the 241T-3037T-14408T-23403G haplotype common in Asia. Despite gene flow among Mexican localities, we found differences in both the allelic frequencies among localities and the allelic imbalance of the mutation S194L of the nucleocapsid protein between symptomatic and asymptomatic carriers. Our results highlight the dual role of Spike and Nucleocapsid proteins in adaptive evolution of SARS-CoV-2 to their hosts and provide a baseline for specific follow-up of mutations of concern during the vaccination stage in Mexico.

IMPACT STATEMENT Following self-sampling, screening of mutations of concern, and a combined phylogenomic and population genetics pipeline, we reveal the occurrence of two variants of interest with mutations in the Spike protein, P.3 (B.1.1.28.3) and 20B/478K.V1 (B.1.1.222, recently named B.1.1.519) in Mexico during the pre-vaccination stage, plus a mutation in the Nucleocapsid protein, S194L, that associates only with symptomatic patients versus asymptomatic carriers in the population investigated. Our research can aid epidemiological genomics efforts during the vaccination stage in Mexico by contributing with a combined analytical platform and information about variants within different genetic backgrounds.

DATA SUMMARY The Mexstrain-Nextstrain data can be found at: http://www.ira.cinvestav.mx/ncov.evol.mex.aspx.

Data generated and used in this study is provided as supplementary Tables:

Table S1. Self-sampling performance validation data generated in 58 volunteers.

Table S2. Metadata of SARS-CoV-2 genomes generated and investigated.

Table S3. Complete dataset of the population genomics analysis of SARS-CoV-2.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

There was no critical trial

Funding Statement

This was funded by a Mexican CONACYT 2020-COVID19 grant to Angelica Cibrian.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical committee clearance. All the RNA samples that are reported in this study were obtained during a surveillance program part of a research protocol compliant with El Comite de Bioetica para la Investigacion en Seres Humanos del Centro de Investigacion y Estudios Avanzados del IPN (COBISH) led by Dr. Betzabe Quintanilla Vega, who approved research for all SARS-CoV-2 carriers in the State of Guanajuato (069/2020). The samples from the State of San Luis Potosi were obtained through the clinical diagnostic service provided by the Centro de Investigacion en Ciencias de la Salud y Biomedicina of the Universidad Autonoma de San Luis Potosi as part of a research protocol compliant with the corresponding local authorities, represented by Dra. Liliana Rangel Martinez according to the Ley Estatal de Salud and NOM-012-SSA3-2012, who approved obtaining and using the samples for this paper (SLP/09-2020). For samples from Jalisco the Laboratory for the Diagnosis of Emerging and Reemerging Diseases (LaDEER), the University of Guadalajara, was compliant with local ethical authorities. Obtaining and using research samples from Jalisco were approved by the Comites de Investigacion, Etica en Investigacion y Bioseguridad de la Universidad de Guadalajara led by Dra. Barbara Vizmanos Lamonte CI- 00821 and CI-00721). Moreover, all samples were treated and contained by international standards of Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19), and all positive diagnostics were informed to patients and the corresponding Health local authorities between 24 and 48 hours of sampling. An informed written consent for the use of surveillance samples was obtained from all patients.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data is available in public databases.

http://www.ira.cinvestav.mx/ncov.evol.mex.aspx

https://github.com/luisdelaye/Mexstrain

https://github.com/plissonf/Phylogenomics_SARS-CoV-2_Mexico

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 18, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Phylogenomics and population genomics of SARS-CoV-2 in Mexico reveals variants of interest (VOI) and a mutation in the Nucleocapsid protein associated with symptomatic versus asymptomatic carriers
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Phylogenomics and population genomics of SARS-CoV-2 in Mexico reveals variants of interest (VOI) and a mutation in the Nucleocapsid protein associated with symptomatic versus asymptomatic carriers
Francisco Barona-Gómez, Luis Delaye, Erik Díaz-Valenzuela, Fabien Plisson, Arely Cruz-Pérez, Mauricio Díaz-Sánchez, Christian A. García-Sepúlveda, Alejandro Sanchez-Flores, Rafael Pérez-Abreu, Francisco J. Valencia-Valdespino, Natali Vega-Magaña, J. Francisco Muñoz-Valle, Octavio P. García-González, Sofía Bernal-Silva, Andreu Comas-García, Angélica Cibrián-Jaramillo
medRxiv 2021.05.18.21256128; doi: https://doi.org/10.1101/2021.05.18.21256128
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Phylogenomics and population genomics of SARS-CoV-2 in Mexico reveals variants of interest (VOI) and a mutation in the Nucleocapsid protein associated with symptomatic versus asymptomatic carriers
Francisco Barona-Gómez, Luis Delaye, Erik Díaz-Valenzuela, Fabien Plisson, Arely Cruz-Pérez, Mauricio Díaz-Sánchez, Christian A. García-Sepúlveda, Alejandro Sanchez-Flores, Rafael Pérez-Abreu, Francisco J. Valencia-Valdespino, Natali Vega-Magaña, J. Francisco Muñoz-Valle, Octavio P. García-González, Sofía Bernal-Silva, Andreu Comas-García, Angélica Cibrián-Jaramillo
medRxiv 2021.05.18.21256128; doi: https://doi.org/10.1101/2021.05.18.21256128

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (500)
  • Anesthesia (110)
  • Cardiovascular Medicine (1226)
  • Dentistry and Oral Medicine (205)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (528)
  • Epidemiology (9999)
  • Forensic Medicine (5)
  • Gastroenterology (497)
  • Genetic and Genomic Medicine (2442)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1634)
  • Health Policy (750)
  • Health Systems and Quality Improvement (633)
  • Hematology (247)
  • HIV/AIDS (530)
  • Infectious Diseases (except HIV/AIDS) (11854)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (251)
  • Medical Ethics (74)
  • Nephrology (267)
  • Neurology (2272)
  • Nursing (139)
  • Nutrition (349)
  • Obstetrics and Gynecology (451)
  • Occupational and Environmental Health (532)
  • Oncology (1244)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (154)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (729)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (281)
  • Psychiatry and Clinical Psychology (2279)
  • Public and Global Health (4822)
  • Radiology and Imaging (833)
  • Rehabilitation Medicine and Physical Therapy (488)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (224)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (124)
  • Urology (99)